Rafael Pharmaceuticals Announces First Patient Enrolled in APOLLO 613 Phase 1/2 Clinical Trial of CPI-613® (Devimistat) in Patients with Relapsed Clear Cell Sarcoma
Stock Information for Rafael Holdings Inc. Class B
Loading
Please wait while we load your information from QuoteMedia.